| Dunn, Michael |
EBONI, NCT05514509: A Study Evaluating Implementation Strategies for the Delivery of APRETUDE for Black cis-and Transgender Women in United States EHE Territories |
|
|
| Completed | 4 | 370 | US | APRETUDE, Cabotegravir tablet | ViiV Healthcare | HIV Infections | 09/25 | 09/25 | | |
NCT06153693: Efficacy and Safety of Lorundrostat in Subjects With Uncontrolled and Resistant Hypertension |
|
|
| Completed | 3 | 1083 | Europe, Canada, US, RoW | Placebo, lorundrostat Dose 1, lorundrostat Dose 2 | Mineralys Therapeutics Inc. | Hypertension | 12/24 | 01/25 | | |
NCT05968430: Open-Label Extension (OLE) Study to Assess Safety, Efficacy, and Tolerability of Lorundrostat in Subjects With Hypertension |
|
|
| Active, not recruiting | 3 | 1076 | Europe, Canada, US, RoW | lorundrostat, Placebo | Mineralys Therapeutics Inc. | Hypertension | 12/25 | 12/26 | | |
NCT05769608: A Pivotal Study to Evaluate the Efficacy of Lorundrostat in Subjects With Uncontrolled Hypertension on a Standardized Antihypertensive Medication Regimen |
|
|
| Completed | 2 | 285 | US | Placebo, lorundrostat Dose 1, lorundrostat Dose 2 | Mineralys Therapeutics Inc. | Hypertension | 01/25 | 01/25 | | |
NCT04845178: Investigation of Safety and Efficacy of ABP-450 for Migraine Prevention in Adults |
|
|
| Completed | 2 | 797 | NA | ABP-450, prabotulinumtoxinA, Placebo, 0.9% sodium chloride, saline | AEON Biopharma, Inc., PPD | Migraine | 06/24 | 08/24 | | |
| Person, Central Contact |
ENIGMA-SC, NCT05152563: A Study to Assess Subcutaneous AK002 in Eosinophilic Gastritis and/or Eosinophilic Duodenitis |
|
|
| Withdrawn | 3 | 280 | US | AK002, Lirentelimab, Placebo | Allakos Inc. | Eosinophilic Gastritis, Eosinophilic Duodenitis | 01/22 | 01/22 | | |
| Terminated | 2 | 131 | Europe, US | AK002, Lirentelimab, Placebo | Allakos Inc., Allakos Inc. | Atopic Dermatitis | 12/23 | 04/24 | | |
| Terminated | 2 | 127 | Europe, US | Lirentelimab (AK002), AK002, Placebo | Allakos Inc., Allakos Inc. | Chronic Spontaneous Urticaria | 12/23 | 04/24 | | |
| Walters, Alton |
NCT06098079: Effect of Naltrexone Hydrochloride ER and Bupropion Hydrochloride ER Combination (Contrave®/Mysimba®) on Major Adverse Cardiovascular Events (MACE) |
|
|
| Recruiting | 4 | 8600 | US | Naltrexone-Bupropion (NB) Combination, Placebo | Currax Pharmaceuticals | Obesity | 01/29 | 07/29 | | |
FORCE2, NCT05292586: A Study Testing the Superiority of CHF 1535 pMDI 800/24µg Total Daily Dose Compared With CHF 718 pMDI 800µg Total Daily Dose in Adults With Asthma on Medium or High-Dose Inhaled Corticosteroid |
|
|
| Completed | 3 | 1377 | US | Beclomethasone Dipropionate/Formoterol Fumarate, BDP/FF, Beclomethasone Dipropionate, BDP | Chiesi Farmaceutici S.p.A. | Asthma | 06/24 | 06/24 | | |
NCT06087640: A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults ≥65 Years of Age |
|
|
| Active, not recruiting | 3 | 35800 | Europe, US, RoW | aQIV or aTIV, Fluad Tetra/Quadrivalent or Fluad, QIV or TIV | Seqirus | Influenza, Human | 11/26 | 12/26 | | |
NCT05769608: A Pivotal Study to Evaluate the Efficacy of Lorundrostat in Subjects With Uncontrolled Hypertension on a Standardized Antihypertensive Medication Regimen |
|
|
| Completed | 2 | 285 | US | Placebo, lorundrostat Dose 1, lorundrostat Dose 2 | Mineralys Therapeutics Inc. | Hypertension | 01/25 | 01/25 | | |
CALM-CSU, NCT06077773: Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of EP262 in Subjects With Chronic Spontaneous Urticaria |
|
|
| Terminated | 2 | 113 | Europe, Canada, US | Oral EP262, Placebo | Escient Pharmaceuticals, Inc | Chronic Spontaneous Urticaria | 12/24 | 01/25 | | |
NCT06865079: 53-Week Study Evaluating the Safety and Efficacy of Intra-articular Injections of TPX-100 With Mild to Severe Tibio-Femoral Osteoarthritis of the Knee |
|
|
| Recruiting | 2 | 270 | US | TPX-100 200mg, Once weekly for 4 weeks, PBS | OrthoTrophix, Inc | Osteoarthritis (OA) of the Knee | 05/27 | 06/27 | | |
| Abdelsayed, Nader |
| Completed | 3 | 183 | US | CCT-102 A and CCT-102 B | Conceptra Biosciences, LLC | Early Pregnancy Loss, Delayed Pregnancy Loss | 05/25 | 07/25 | | |
